Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer Metastatic
Female
Breast Cancer Metastatic
Trial Information
Phase 1B Study Of Docetaxel + PF-03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
Inclusion Criteria:
- Diagnosis of breast cancer with evidence of a) metastatic or b) locally
recurrent/advanced disease.
Exclusion Criteria:
- Prior treatment with a gamma secretase inhibitors or other Notch signaling
inhibitors.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Number of participants with Dose-limiting toxicities (DLT)
Outcome Time Frame:
21 days
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A8641016
NCT ID:
NCT01876251
Start Date:
August 2013
Completion Date:
August 2015
Related Keywords:
- Breast Cancer Metastatic
- Breast cancer metastatic
- docetaxel
- PF-03084014
- Breast Neoplasms
- Neoplasms
- Neoplasms, Second Primary
Name | Location |
|---|
